Cargando…

Expanding applications of MRI-based radiomics in HER2-positive breast cancer

Detalles Bibliográficos
Autor principal:	Park, Vivian Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578668/ https://www.ncbi.nlm.nih.gov/pubmed/33096473 http://dx.doi.org/10.1016/j.ebiom.2020.103085

Ejemplares similares

MRI-Based Radiomic Signature as a Prognostic Biomarker for HER2-Positive Invasive Breast Cancer Treated with NAC
por: Li, Qin, et al.
Publicado: (2020)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
por: Moya-Horno, I, et al.
Publicado: (2015)

MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 − Early Breast Cancer Patients
por: Chiacchiaretta, Piero, et al.
Publicado: (2023)

Radiomics Nomogram Based on Radiomics Score from Multiregional Diffusion-Weighted MRI and Clinical Factors for Evaluating HER-2 2+ Status of Breast Cancer
por: Li, Chunli, et al.
Publicado: (2021)

Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?
por: Solinas, Cinzia, et al.
Publicado: (2021)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
por: Rayson, Daniel, et al.
Publicado: (2022)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer
por: Bitencourt, Almir G.V., et al.
Publicado: (2020)

The Application of Radiomics in Breast MRI: A Review
por: Ye, Dong-Man, et al.
Publicado: (2020)

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer
por: Okines, Dr Alicia FC, et al.
Publicado: (2021)

Expanding the application of cancer near-infrared photoimmunotherapy
por: Kobayashi, Hisataka
Publicado: (2021)

Value of Machine Learning with Multiphases CE-MRI Radiomics for Early Prediction of Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Invasive Breast Cancer
por: Li, Qin, et al.
Publicado: (2021)

American Society of Clinical Oncology 2021 Podcast: HR+, HER2− Breast Cancer
por: Cheung, Kwok-Leung
Publicado: (2021)

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
por: Isca, Chrystel, et al.
Publicado: (2021)

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
por: Corti, C., et al.
Publicado: (2021)

Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases
por: Lin, N.U.
Publicado: (2022)

MRI Radiomic Features: Association with Disease-Free Survival in Patients with Triple-Negative Breast Cancer
por: Kim, Sungwon, et al.
Publicado: (2020)

Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features
por: Park, Jiwoo, et al.
Publicado: (2023)

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
por: Arteaga, Carlos L
Publicado: (2003)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
por: Hong, Joohyun, et al.
Publicado: (2022)

Redefining and expanding the sphere of influence of BRCA in breast and colorectal cancers and beyond
por: Lou, Emil
Publicado: (2022)

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer
por: Braman, Nathaniel, et al.
Publicado: (2019)

HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast
por: Bardia, Aditya, et al.
Publicado: (2023)

Commentary: Expanding the Surgical Indications in Lung Cancer
por: Park, Seong Yong
Publicado: (2023)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Assessing the Clinical Utility of Computed Tomography‐Based Radiomics
por: Lai‐Kwon, Julia, et al.
Publicado: (2018)

MRI radiomics and potential applications to glioblastoma
por: Hooper, Grayson W., et al.
Publicado: (2023)

Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
por: Yap, Y S, et al.
Publicado: (2012)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Development and Validation of an Ultrasound-Based Radiomics Nomogram for Identifying HER2 Status in Patients with Breast Carcinoma
por: Guo, Yinghong, et al.
Publicado: (2022)

Deep learning radiomics model based on breast ultrasound video to predict HER2 expression status
por: Quan, Meng-Yao, et al.
Publicado: (2023)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients
por: Ha, June-Hyung, et al.
Publicado: (2014)

Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
por: Chen, Wei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rqt7m7k1v5m9sr9tntk9adkk2e